Details
Title
Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
Author
Poels, Kamrine E. 1
; Schoenfeld, Adam J. 2 ; Makhnin, Alex 2 ; Tobi, Yosef 2
; Wang, Yuli 3 ; Frisco-Cabanos, Heidie 4 ; Chakrabarti, Shaon 5 ; Shi, Manli 3 ; Napoli, Chelsi 4 ; McDonald, Thomas O. 6 ; Tan, Weiwei 7 ; Hata, Aaron 8 ; Weinrich, Scott L. 3 ; Yu, Helena A. 2 ; Michor, Franziska 9
1 Harvard T.H. Chan School of Public Health, Department of Biostatistics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana Farber Cancer Institute, Department of Data Science, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
2 Weill Cornell Medical College, Division of Solid Tumor Oncology, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
3 Pfizer Inc, Oncology Research and Development, La Jolla, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493)
4 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
5 Harvard T.H. Chan School of Public Health, Department of Biostatistics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana Farber Cancer Institute, Department of Data Science, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Harvard University, Department of Stem Cell and Regenerative Biology, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
6 Harvard T.H. Chan School of Public Health, Department of Biostatistics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana Farber Cancer Institute, Department of Data Science, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Harvard University, Department of Stem Cell and Regenerative Biology, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana-Farber Cancer Institute, The Center for Cancer Evolution, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
7 Pfizer Inc, Clinical Pharmacology Oncology, Global Product Development, San Diego, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493)
8 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); The Ludwig Center at Harvard, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Department of Medicine, Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
9 Harvard T.H. Chan School of Public Health, Department of Biostatistics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana Farber Cancer Institute, Department of Data Science, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Harvard University, Department of Stem Cell and Regenerative Biology, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana-Farber Cancer Institute, The Center for Cancer Evolution, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); The Ludwig Center at Harvard, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); The Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623)
; Schoenfeld, Adam J. 2 ; Makhnin, Alex 2 ; Tobi, Yosef 2
; Wang, Yuli 3 ; Frisco-Cabanos, Heidie 4 ; Chakrabarti, Shaon 5 ; Shi, Manli 3 ; Napoli, Chelsi 4 ; McDonald, Thomas O. 6 ; Tan, Weiwei 7 ; Hata, Aaron 8 ; Weinrich, Scott L. 3 ; Yu, Helena A. 2 ; Michor, Franziska 9
1 Harvard T.H. Chan School of Public Health, Department of Biostatistics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana Farber Cancer Institute, Department of Data Science, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
2 Weill Cornell Medical College, Division of Solid Tumor Oncology, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
3 Pfizer Inc, Oncology Research and Development, La Jolla, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493)
4 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
5 Harvard T.H. Chan School of Public Health, Department of Biostatistics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana Farber Cancer Institute, Department of Data Science, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Harvard University, Department of Stem Cell and Regenerative Biology, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
6 Harvard T.H. Chan School of Public Health, Department of Biostatistics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana Farber Cancer Institute, Department of Data Science, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Harvard University, Department of Stem Cell and Regenerative Biology, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana-Farber Cancer Institute, The Center for Cancer Evolution, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
7 Pfizer Inc, Clinical Pharmacology Oncology, Global Product Development, San Diego, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493)
8 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); The Ludwig Center at Harvard, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Department of Medicine, Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
9 Harvard T.H. Chan School of Public Health, Department of Biostatistics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana Farber Cancer Institute, Department of Data Science, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Harvard University, Department of Stem Cell and Regenerative Biology, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana-Farber Cancer Institute, The Center for Cancer Evolution, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); The Ludwig Center at Harvard, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); The Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623)
Publication year
2022
Publication date
2022
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2717204034
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.